Search Results - "Yarchoan, Mark"

Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease by YARCHOAN, Mark, ARNOLD, Steven E

“…A growing body of clinical and epidemiological research suggests that two of the most common diseases of aging, type 2 diabetes (T2DM) and Alzheimer disease…”
Get full text

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma by Singal, Amit G, Llovet, Josep M, Yarchoan, Mark, Mehta, Neil, Heimbach, Julie K, Dawson, Laura A, Jou, Janice H, Kulik, Laura M, Agopian, Vatche G, Marrero, Jorge A, Mendiratta-Lala, Mishal, Brown, Daniel B, Rilling, William S, Goyal, Lipika, Wei, Alice C, Taddei, Tamar H

Get full text

Strategies for Increasing Pancreatic Tumor Immunogenicity by Johnson, 3rd, Burles A, Yarchoan, Mark, Lee, Valerie, Laheru, Daniel A, Jaffee, Elizabeth M

“…Immunotherapy has changed the standard of care for multiple deadly cancers, including lung, head and neck, gastric, and some colorectal cancers. However,…”
Get full text

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers by Yarchoan, Mark, Albacker, Lee A, Hopkins, Alexander C, Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T, Zaidi, Neeha, Azad, Nilofer S, Laheru, Daniel A, Frampton, Garrett M, Jaffee, Elizabeth M

“…PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These…”
Get full text

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma by Mi, Haoyang, Ho, Won Jin, Yarchoan, Mark, Popel, Aleksander S

“…Concomitant inhibition of vascular endothelial growth factor (VEGF) and programmed cell death protein 1 (PD-1) or its ligand PD-L1 is a standard of care for…”
Get full text

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity by Anagnostou, Valsamo, Yarchoan, Mark, Hansen, Aaron R, Wang, Hao, Verde, Franco, Sharon, Elad, Collyar, Deborah, Chow, Laura Q M, Forde, Patrick M

“…Immuno-oncology (I-O) has required a shift in the established paradigm of toxicity and response assessment in clinical research. The design and interpretation…”
Get full text

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas by Ho, Won Jin, Yarchoan, Mark, Hopkins, Alex, Mehra, Ranee, Grossman, Stuart, Kang, Hyunseok

“…Low absolute lymphocyte count (ALC) has previously been established as a marker of poor prognosis in multiple cancer types. There is growing evidence that ALC…”
Get full text

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade by Stein, Julie E, Lipson, Evan J, Cottrell, Tricia R, Forde, Patrick M, Anders, Robert A, Cimino-Mathews, Ashley, Thompson, Elizabeth D, Allaf, Mohamad E, Yarchoan, Mark, Feliciano, Josephine, Wang, Hao, Jaffee, Elizabeth M, Pardoll, Drew M, Topalian, Suzanne L, Taube, Janis M

“…Pathologic response assessment of tumor specimens from patients receiving systemic treatment provides an early indication of therapeutic efficacy and predicts…”
Get full text

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma by Yarchoan, Mark, Xing, Dongmei, Luan, Lan, Xu, Haiying, Sharma, Rajni B, Popovic, Aleksandra, Pawlik, Timothy M, Kim, Amy K, Zhu, Qingfeng, Jaffee, Elizabeth M, Taube, Janis M, Anders, Robert A

“…Hepatocellular carcinoma (HCC) often arises in the setting of chronic liver inflammation and may be responsive to novel immunotherapies. To characterize the…”
Get full text

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence by Zhang, Shuming, Yuan, Long, Danilova, Ludmila, Mo, Guanglan, Zhu, Qingfeng, Deshpande, Atul, Bell, Alexander T F, Elisseeff, Jennifer, Popel, Aleksander S, Anders, Robert A, Jaffee, Elizabeth M, Yarchoan, Mark, Fertig, Elana J, Kagohara, Luciane T

“…Novel immunotherapy combination therapies have improved outcomes for patients with hepatocellular carcinoma (HCC), but responses are limited to a subset of…”
Get full text

Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways by Ho, Won Jin, Erbe, Rossin, Danilova, Ludmila, Phyo, Zaw, Bigelow, Emma, Stein-O'Brien, Genevieve, Thomas, 2nd, Dwayne L, Charmsaz, Soren, Gross, Nicole, Woolman, Skylar, Cruz, Kayla, Munday, Rebecca M, Zaidi, Neeha, Armstrong, Todd D, Sztein, Marcelo B, Yarchoan, Mark, Thompson, Elizabeth D, Jaffee, Elizabeth M, Fertig, Elana J

“…The majority of pancreatic ductal adenocarcinomas (PDAC) are diagnosed at the metastatic stage, and standard therapies have limited activity with a dismal…”
Get full text

Systemic inhibition of PTPN22 augments anticancer immunity by Ho, Won Jin, Croessmann, Sarah, Lin, Jianping, Phyo, Zaw H, Charmsaz, Soren, Danilova, Ludmila, Mohan, Aditya A, Gross, Nicole E, Chen, Fangluo, Dong, Jiajun, Aggarwal, Devesh, Bai, Yunpeng, Wang, Janey, He, Jing, Leatherman, James M, Yarchoan, Mark, Armstrong, Todd D, Zaidi, Neeha, Fertig, Elana J, Denny, Joshua C, Park, Ben H, Zhang, Zhong-Yin, Jaffee, Elizabeth M

“…Both epidemiologic and cellular studies in the context of autoimmune diseases have established that protein tyrosine phosphatase non-receptor type 22 (PTPN22)…”
Get full text

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity by Yarchoan, Mark, Mohan, Aditya A, Dennison, Lauren, Vithayathil, Teena, Ruggieri, Amanda, Lesinski, Gregory B, Armstrong, Todd D, Azad, Nilofer S, Jaffee, Elizabeth M

“…Mitogen-activated protein kinase (MAPK) kinase (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor…”
Get full text

Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial by Baretti, Marina, Danilova, Ludmila, Durham, Jennifer N., Betts, Courtney B., Cope, Leslie, Sidiropoulos, Dimitrios N., Tandurella, Joseph A., Charmsaz, Soren, Gross, Nicole, Hernandez, Alexei, Ho, Won Jin, Thoburn, Chris, Walker, Rosalind, Leatherman, James, Mitchell, Sarah, Christmas, Brian, Saeed, Ali, Gaykalova, Daria A., Yegnasubramanian, Srinivasan, Fertig, Elana J., Coussens, Lisa M., Yarchoan, Mark, Jaffee, Elizabeth, Azad, Nilofer S.

“…Pancreatic ductal adenocarcinoma (PDA) is characterized by low cytotoxic lymphocytes, abundant immune-suppressive cells, and resistance to immune checkpoint…”
Get full text

Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model by Sové, Richard J, Verma, Babita K, Wang, Hanwen, Ho, Won Jin, Yarchoan, Mark, Popel, Aleksander S

“…BackgroundHepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is the third-leading cause of cancer-related death worldwide. Most…”
Get full text

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma by Ho, Won Jin, Danilova, Ludmila, Lim, Su Jin, Verma, Rohan, Xavier, Stephanie, Leatherman, James M, Sztein, Marcelo B, Fertig, Elana J, Wang, Hao, Jaffee, Elizabeth, Yarchoan, Mark

“…Background and aimsImmune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway have…”
Get full text

825 High-dimensional image cytometry reveals spatially organized tumor-immune microenvironment in hepatocellular carcinoma by Mi, Haoyang, Popel, Aleksander, Yarchoan, Mark

“…BackgroundStructured and spatial-nuanced interactions between components in tumor microenvironment (TME) regulates the efficacy of anti-tumor regimens…”
Get full text

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures by Mody, Kabir, Jain, Prerna, El-Refai, Sherif M, Azad, Nilofer S, Zabransky, Daniel J, Baretti, Marina, Shroff, Rachna T, Kelley, R Katie, El-Khouiery, Anthony B, Hockenberry, Adam J, Lau, Denise, Lesinski, Gregory B, Yarchoan, Mark

“…Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and…”
Get more information

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer by Yarchoan, Mark, Huang, Chiung‐Yu, Zhu, Qingfeng, Ferguson, Anna K., Durham, Jennifer N., Anders, Robert A., Thompson, Elizabeth D., Rozich, Noah S., Thomas, Dwayne L., Nauroth, Julie M., Rodriguez, Christina, Osipov, Arsen, De Jesus‐Acosta, Ana, Le, Dung T., Murphy, Adrian G., Laheru, Daniel, Donehower, Ross C., Jaffee, Elizabeth M., Zheng, Lei, Azad, Nilofer S.

“…Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor…”
Get full text

Ipilimumab-Induced Enteritis without Colitis: A New Challenge by Messmer, Marcus, Upreti, Sunita, Tarabishy, Yaman, Mazumder, Nikhilesh, Chowdhury, Reezwana, Yarchoan, Mark, Holdhoff, Matthias

“…Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic…”
Get full text